HC Wainwright & Co. Reiterates Buy on Insmed, Maintains $52 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Insmed (NASDAQ:INSM) and maintained a price target of $52.

August 04, 2023 | 3:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Insmed's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $52.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $52 indicates the firm's continued confidence in the company's potential. This could lead to increased investor confidence and potentially a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100